Kwality Pharmaceuticals Ltd (KPL) — shareholding pattern, promoter holding, financials and share price

About Kwality Pharmaceuticals Ltd (KPL)

Kwality Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as KPL and on the BSE under scrip code 539997. Its ISIN is INE552U01010.

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products [1]

Kwality Pharmaceuticals is an India-based finished dosage and complex injectables manufacturer and CDMO focusing on injectables, biologics, oncology formulations and beta-lactams; it sells primarily by out-licensing and supply across 70+ countries and operates multiple EU/PICs/WHO-accredited manufacturing units with an active R&D centre recognised by DSIR.

Export-led, asset-light model: about 90% of revenue comes from out-licensing and supply while CDMO contributes ~10%, enabling rapid international expansion with limited front-end commercial risk and a filing cadence that rose from 75 (FY23) to 200 (FY26). This strategic mix drives stable export revenues but lengthens receivable cycles.

Listed peers in Pharmaceuticals: Hikal Ltd, Solara Active Pharma Sciences Ltd, Sai Parenterals Ltd, Indoco Remedies Ltd, Beta Drugs Ltd, Venus Remedies Ltd.

Valuation & Returns

10 Jul 2026

At ₹2,614.2 a share on 10 Jul 2026, Kwality Pharmaceuticals Ltd (KPL) was valued at a price-to-earnings ratio of 40.28x against an industry P/E of 36.41x and a price-to-book of 10.27x on a book value of ₹254.48 per share as of Mar 2025. Solomo computes return on equity of 25.51% and return on capital employed of 26.69% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
40.28x
Industry P/E
36.41x
P/B
10.27x
EPS (TTM)
₹64.91
Book value / share
₹254.48
ROE
25.51%
ROCE
26.69%
ROA
15.06%
Debt / equity
0.43x
Dividend yield
0%
EBITDA margin
23.91%
52-week range
₹828.8 – ₹2,889

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Kwality Pharmaceuticals Ltd (KPL) reported revenue of ₹503 crore, net profit of ₹67 crore and earnings per share of ₹64.91. That compares with revenue of ₹370 crore and net profit of ₹40 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹157 crore and net profit ₹25 crore (consolidated).

Consolidated annual results for Kwality Pharmaceuticals Ltd (KPL), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)456251307370503
Net profit (₹ cr)12019244067
EPS (₹)115.6418.6722.9438.4164.91
Compound annual growth for Kwality Pharmaceuticals Ltd (KPL). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth19.26%21.70%-6.72%20.52%
Profit growth40.37%36.46%-30.74%68.50%
Stock price CAGR62%74%102%142%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 54.86% of Kwality Pharmaceuticals Ltd (KPL) (down 0.01 pp QoQ), foreign institutional investors (FII) hold 3.13% and domestic institutional investors (DII) hold 0.56%. Market capitalisation was ₹2,713 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2016.

Largest disclosed public shareholders in Jun 2026: DEEPAK BANSAL 8.39%, MANOHAR DEVABHAKTUNI 4.98%, ARK GLOBAL EMERGING COMPANIES, LP 2.11%, KADAYAM RAMNATHAN BHARAT 1.98%, DHEERAJ KUMAR LOHIA 1.66%, JANI BHASHA SHAIK 1.45%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202654.86%-3.13%0.56%45.14%
Mar 202654.87%-2.79%0.36%45.13%
Dec 202554.83%-0.5%0.33%45.17%
Sep 202554.83%--0.33%45.17%
Jun 202554.83%--0.33%45.17%
Mar 202554.83%--0.32%45.17%
Dec 202454.83%--0.03%45.17%
Sep 202454.83%--0.02%45.17%
Every quarter since Sep 2016 Filing data, not investment advice.